Clinical trials: Breast Cancer, Female
Hot Flushes, Hot Flashes
Stellate Ganglion Block (SGB) For Women for Breast Cancer
Vasomotor symptoms (VMS) affect up to 65% of breast cancer survivors and negatively impact their quality of life. The investigators aim to evaluate the benefit of SGB in symptomatic women with breast cancer who are on…
- Trial name
- NCT02513329
- Testing
- Bupivicaine, Saline
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Northwestern University
Breast Cancer Female
Predictors of Adjuvant Endocrine Therapy in Women With Breast Cancer
Breast cancer is the leading cancer diagnosed in women and the second cause of cancer death. Of all racial/ethnic groups in the US, Black women have the highest rate of breast cancer deaths.
- Trial name
- WHIP (NCT02992730)
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Neoplasms, Breast
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC).
- Trial name
- NCT00709761
- Testing
- Lapatinib/nab-Paclitaxel
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer Female, Infertility, Female
Impact of Breast Cancer on Human Folliculogenesis
Advances in cancer diagnosis and treatments have improved the 5-year survival rate for patients over the last decade. Nevertheless, cancer treatments frequently alter patient's fertility, thus compromising their ability to…
- Trial name
- FERTICAN (NCT07148141)
- Testing
- Ovarian stimulation
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
Breast Cancer Female, Thyroid Gland
Evaluation of Thyroid Abnormity Incidence and Thyroid Toxicity During Chemotherapy Among Newly Diagnosed Breast Cancer
Breast cancer is one of the most common cancers in China. Even though advances in the field of breast cancer therapeutics, chemotherapy remains the mainstay therapeutic modality.
- Trial name
- NCT03177902
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Solid Tumors, High Grade Gliomas
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
Study aimed to assess the reproducibility of PET imaging using AH111585 (18F) Injection. Subjects are evaluable if they undergo 2 administrations of AH111585 (18F) Injection (3 to 8 days apart) and the corresponding PET…
- Conditions
- Solid Tumors, High Grade Gliomas, Lung Cancer, Head and Neck Cancer
- Trial name
- NCT00918281
- Testing
- Fluciclatide Injection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- GE Healthcare
Breast Cancer, Ovarian Cancer
Guilford Genomic Medicine Initiative (GGMI)
Genomic medicine, using genetic information to improve health outcomes, is heralded as the answer to rising medical costs by focusing on prevention and tailored care.
- Conditions
- Breast Cancer, Ovarian Cancer, Colon Cancer, Thrombophilia
- Trial name
- GGMI (NCT01372553)
- Where
- United States
- Volunteers
- 1,184 people, healthy volunteers welcome
- Sponsor
- The Moses H. Cone Memorial Hospital
Breast Cancer
Herbal Therapy in Treating Women With Metastatic Breast Cancer
RATIONALE: The Chinese herb Scutellaria barbata contains ingredients that may slow the growth of cancer cells and may be an effective treatment for metastatic breast cancer.
- Trial name
- NCT00028977
- Testing
- herba scutellaria barbata, herba scutellaria Barbatae (HSB)
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Vaginal Atrophy in Breast Cancer Patients
Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on moderate to severe (MS) and most bothersome symptoms (MBS) of vulvovaginal atrophy (VVA) due to natural, surgical or treatment-induced…
- Trial name
- NCT03740945
- Testing
- Prasterone (DHEA)
- Sponsor
- EndoCeutics Inc.
Breast Cancer
InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2
The purpose of the study is to obtain and centralize data about cancer prevention strategies in women with a germline deleterious mutation in BRCA1-2 with or without a history of breast cancer in Italy
- Trial name
- IDENTITY (NCT05835739)
- Where
- 12 sites in Italy
- Volunteers
- 78 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Cancer of the Breast, Cancer of Stomach
Vocorder Device Validation in Clinical Settings - Continuous Monitoring of Individuals (Vocorder Clinical Validation-VCV)
This is performed under Vocorder project that is Co-Funded by the European Union. (Grant Agreement 101115442 VOCORDER HORIZON EIC-2022-PATHFINDERCHALLENGE-01).
- Conditions
- Cancer of the Breast, Cancer of Stomach, Colon Cancer, Lung Cancers
- Trial name
- VCV (NCT06711939)
- Where
- Greece
- Volunteers
- 515 people, healthy volunteers welcome
- Sponsor
- Mitera Hospital
Breast Cancer, Breast Cancer Stage II
Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
This is a two-stage phase II study with a single arm design. It will be conducted in women with breast cancer with stages IIA to IIIC (defined by AJCC 2009 classification) of all histological subtypes.
- Conditions
- Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III
- Trial name
- NCT03058939
- Testing
- Paclitaxel, Perjeta, Herceptin SC
- Where
- Nigeria
- Sponsor
- University of Chicago
Breast Cancer
Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential
This study is to assess the pharmacokinetics (PK) of a single dose of pravastatin with and without concomitant GDC-0810 administration in healthy female subjects of non-childbearing potential.
- Trial name
- NCT02621957
- Testing
- GDC-0810, Pravastatin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Breast Cancer Females
Short-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. While there is a clear linear relationship between the duration of aromatase inhibitor use and the cumulative incidence of…
- Trial name
- STRIVE (Acute) (NCT06781762)
- Testing
- N/A (Usual Care)
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Breast Neoplasm Female, Ultrasound Therapy; Complications
Mayo Designed Soft Tissue Ultrasound-Detectable Marker
Researchers are trying to determine if the Mayo marker is easily seen with ultrasound making it easier, faster, and more accurate for preoperative localization of the biopsied positive lymph node.
- Trial name
- NCT04674852
- Testing
- Research Marker
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Her2 Negative Breast Cancer Patients
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
To determine whether the combination MM-121 + Exemestane in ER+ and/or PR+ breast cancer patients is more effective than Exemestane alone
- Trial name
- NCT01151046
- Testing
- MM-121, Exemestane
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 118 people
- Sponsor
- Merrimack Pharmaceuticals
Anxiety Disorder, Breast Cancer
Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Acupuncture may help relieve muscle and bone pain caused by aromatase inhibitor therapy, such as letrozole, exemestane, and anastrozole.
- Conditions
- Anxiety Disorder, Breast Cancer, Depression, Fatigue
- Trial name
- NCT00641303
- Testing
- acupuncture therapy
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- University of Maryland, Baltimore
Female Breast Carcinoma, Breast Cancer
Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
This is an open-label, pilot study designed to evaluate the safety and feasibility of combining anastrozole and palbociclib in the following two cohorts: Cohort A) as first-line therapy and Cohort B) as maintenance therapy after…
- Trial name
- NCT02942355
- Testing
- anastrozole, Palbociclib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Ovarian Cancer
A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services
The goal of this research is to evaluate the relative advantage of remote counseling over usual care in community health practices without access to genetic services.
- Conditions
- Breast Cancer, Ovarian Cancer, Colorectal Cancer
- Trial name
- NCT02517554
- Testing
- Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site, Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site, Patient receives written information on how to find genetic services in their area
- Where
- 7 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine